Almanac 2013: stable coronary artery disease

[1] Nabel EG, Braunwald E. A tale of coronary artery disease and myocardial infarction. N Engl J Med 2012;366:54-63.10.1056/NEJMra111257022216842Search in Google Scholar

[2] Briffa T, Nedkoff L, Peeters A, et al. Discordant age and sex-specific trends in the incidence of a first coronary heart disease event in Western Australia from 1996 to2007. Heart 2011;97:400-4.10.1136/hrt.2010.21013821212133Search in Google Scholar

[3] Vaartjes I, O’Flaherty M, Grobbee DE, et al. Coronary heart disease mortality trends in the Netherlands 1972-2007. Heart 2011;97:569-73.10.1136/hrt.2010.20656521282134Search in Google Scholar

[4] Schmidt M, Jacobsen JB, Lash TL, et al. 25 year trends in first time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study. BMJ 2012;344:e356.10.1136/bmj.e356326642922279115Search in Google Scholar

[5] Smolina K, Wright FL, Rayner M, et al. Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study. BMJ 2012;344:d8059.10.1136/bmj.d8059326643022279113Search in Google Scholar

[6] Nedkoff L, Briffa TG, Knuiman M, et al. Temporal trends in the incidence and recurrence of hospitalised atherothrombotic disease in an Australian population, 2000-07: data linkage study. Heart 2012;98:1449-56.10.1136/heartjnl-2012-30218122821274Search in Google Scholar

[7] Pearson-Stuttard J, Bajekal M, Scholes S, et al. Recent UK trends in the unequal burden of coronary heart disease.Heart 2012;98:1573-82.10.1136/heartjnl-2012-30243522888164Search in Google Scholar

[8] Kharazmi E, Dossus L, Rohrmann S, et al. Pregnancy loss and risk of cardiovascular disease: a prospective population-based cohort study (EPIC-Heidelberg). Heart 2011;97:49-54.10.1136/hrt.2010.20222621123827Search in Google Scholar

[9] Safford MM, Brown TM, Muntner PM, et al. Association of race and sex with risk of incident acute coronary heart disease events. JAMA 2012;308:1768-74.10.1001/jama.2012.14306377263723117777Search in Google Scholar

[10] Williams ED, Stamatakis E, Chandola T, et al. Physical activity behaviour and coronary heart disease mortality among South Asian people in the UK: an observational longitudinal study. Heart 2011;97:655-9.10.1136/hrt.2010.20101221131381Search in Google Scholar

[11] Zaman MJ, Bhopal RS. New answers to three questions on the epidemic of coronary mortality in south Asians: incidence or case fatality? Biology or environment? Will the next generation be affected? Heart 2013;99:154-8.10.1136/heartjnl-2012-30236422888157Search in Google Scholar

[12] Fihn SD, Gardin JM, Abrams J, et al.; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; American College of Physicians; American Association for Thoracic Surgery; Preventive Cardiovascular Nurses Association; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. ACCF/AHA/ACP/AATS/PCNA/ SCAI/STS Guideline for the diagnosis andmanagement of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.J Am Coll Cardiol 2012;60:e44-164.Search in Google Scholar

[13] Cooper A, Timmis A, Skinner J. Guideline Development Group. Assessment of recent onset chest pain or discomfort of suspected cardiac origin: summary of NICE guidance.BMJ 2010;340:c1118.10.1136/bmj.c111820335334Search in Google Scholar

[14] Henderson RA, O’Flynn N; Guideline Development Group. Management of stable angina: summary of NICE guidance. Heart 2012;98:500-7.10.1136/heartjnl-2011-30143622275526Search in Google Scholar

[15] Taggart DP, Boyle R, de Belder MA, et al. The 2010ESC/EACTS guidelines on myocardial revascularization.Heart 2011;97:445-6.10.1136/hrt.2010.21613521156673Search in Google Scholar

[16] Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009;360:961-72.10.1056/NEJMoa080462619228612Search in Google Scholar

[17] D’Ascenzo F, Presutti DG, Picardi E, et al. Prevalence and non-invasive predictors of left main or three-vessel coronary disease: evidence from a collaborative international meta-analysis including 22 740 patients. Heart 2012;98:914-9.10.1136/heartjnl-2011-30159622626899Search in Google Scholar

[18] Cacoub PP, Zeymer U, Limbourg T, et al. Effects of adherence to guidelines for the control of major cardiovascular risk factors on outcomes in the REduction of Atherothrombosis for Continued Health (REACH) Registry Europe. Heart 2011;97:660-7.10.1136/hrt.2010.21371021357372Search in Google Scholar

[19] Kotseva K, Jennings CS, Turner EL, et al. A survey of lifestyle, risk factor management and cardioprotective medication in patients with coronary heart disease and people at high risk of developing cardiovascular disease in the UK. Heart 2012;98:865-71.10.1136/heartjnl-2011-30160322581735Search in Google Scholar

[20] Stewart K, Walters M, Dawson J. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (NICE technology appraisal guidance 90). Heart 2011;97:585-6.10.1136/hrt.2010.21971721378012Search in Google Scholar

[21] Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354e62.10.1056/NEJMoa080917119106084Search in Google Scholar

[22] Bouman HJ, Harmsze AM, van Werkum JW, et al.Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. Heart 2011;97:1239-44.10.1136/hrt.2010.22050921628721Search in Google Scholar

[23] Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis.J Am Coll Cardiol 2010;56:134e43.10.1016/j.jacc.2009.12.07120620727Search in Google Scholar

[24] Zabalza M, Subirana I, Sala J, et al. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart 2012;98:100-8.10.1136/hrt.2011.22765221693476Search in Google Scholar

[25] Holmes MV, Perel P, Shah T, et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.JAMA 2011;306:2704-14.10.1001/jama.2011.188022203539Search in Google Scholar

[26] Focks JJ, Brouwer MA, van Oijen MG, et al. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome - a systematic review. Heart 2013;99:520-7.10.1136/heartjnl-2012-30237122851683Search in Google Scholar

[27] Park KW, Kang J, Park JJ, et al. Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. Heart 2012;98:1366-72.10.1136/heartjnl-2012-30189222735685Search in Google Scholar

[28] Li AY, Ng FH, Chan FK, et al. Effect of amlodipine on platelet inhibition by clopidogrel in patients with ischaemic heart disease: a randomised, controlled trial.Heart 2013;99:468-73.10.1136/heartjnl-2012-30280123118347Search in Google Scholar

[29] Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease.N Engl J Med 2011;365:2078-87.10.1056/NEJMoa111087422085316Search in Google Scholar

[30] The AIM-HIGH Investigators. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy.N Engl J Med 2011;365:2255-67.10.1056/NEJMoa110757922085343Search in Google Scholar

[31] Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22.10.1056/NEJMoa070662817984165Search in Google Scholar

[32] Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome.N Engl J Med 2012;367:2089-99.10.1056/NEJMoa1206797Search in Google Scholar

[33] Cannon CP, Shah S, Dansky HM, et al. Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363:2406-15.10.1056/NEJMoa1009744Search in Google Scholar

[34] Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011;306:2099-109.10.1001/jama.2011.1649Search in Google Scholar

[35] Neefjes LA, Ten Kate GJ, Rossi A, et al. CT coronary plaque burden in asymptomatic patients with familial hypercholesterolaemia.Heart 2011;97:1151-7.10.1136/hrt.2010.220699Search in Google Scholar

[36] Cuchel M, Meagher EA, du Toit, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013;381:40-6.10.1016/S0140-6736(12)61731-0Search in Google Scholar

[37] Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012;380:29-36.10.1016/S0140-6736(12)60771-5Search in Google Scholar

[38] Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012;126:2408-17.10.1161/CIRCULATIONAHA.112.144055Search in Google Scholar

[39] Nherera L, Marks D, Minhas R, et al. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart 2011;97:1175-81.10.1136/hrt.2010.213975Search in Google Scholar

[40] Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 2013;381:1293-301.10.1016/S0140-6736(12)62127-8Search in Google Scholar

[41] Gray J, Jaiyeola A, Whiting M, et al. Identifying patients with familial hypercholesterolaemia in primary care: an informatics-based approach in one primary care centre.Heart 2008;94:754-8.10.1136/hrt.2006.10739117575326Search in Google Scholar

[42] Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease.N Engl J Med 2007;356:1503-16.10.1056/NEJMoa070829Search in Google Scholar

[43] Weintraub WS, Spertus JA, Kolm P, et al. Effect of PCI on quality of life in patients with stable coronary disease.N Engl J Med 2008;359:677-87.10.1056/NEJMoa072771Search in Google Scholar

[44] Stergiopoulos K, Brown DL. Initial coronary stent implantation with medical therapy vs medical therapy alone for stable coronary artery disease: meta-analysis of randomized controlled trials. Arch Intern Med 2012;172:312-19.10.1001/archinternmed.2011.1484Search in Google Scholar

[45] Borden WB, Redberg RF, Mushlin AI, et al. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention. JAMA 2011;305:1882-9.10.1001/jama.2011.601Search in Google Scholar

[46] De Bruyne B, Pijls NH, Kalesan B, et al. FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 2012;367:991-1001.10.1056/NEJMoa1205361Search in Google Scholar

[47] Boden WE. COURAGE 5 years on: the message grows stronger. Heart 2012;98:1757-60.10.1136/heartjnl-2012-302823Search in Google Scholar

[48] Hillis LD, Smith PK, Anderson JL, et al. American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; Society of Cardiovascular Anesthesiologists; Society of Thoracic Surgeons. ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons.J Am Coll Cardiol 2011;58:e123-210.Search in Google Scholar

[49] Farooq V, Brugaletta S, Serruys PW. Contemporary and evolving risk scoring algorithms for percutaneous coronary intervention. Heart 2011;97:1902-13.10.1136/heartjnl-2011-300718Search in Google Scholar

[50] Hlatky MA, Boothroyd DB, Baker L, et al. Comparative effectiveness of multivessel coronary bypass surgery and multivessel percutaneous coronary intervention: a cohort study. Ann Intern Med 2013;158:727-34.10.7326/0003-4819-158-10-201305210-00639Search in Google Scholar

[51] Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al.Comparative effectiveness of revascularization strategies.N Engl J Med 2012;366:1467-76.10.1056/NEJMoa1110717Search in Google Scholar

[52] Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013;381:629-38.10.1016/S0140-6736(13)60141-5Search in Google Scholar

[53] Farkouh ME, Domanski M, Sleeper LA, et al. FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012;367:2375-84.10.1056/NEJMoa121158523121323Search in Google Scholar

[54] Chieffo A, Meliga E, Latib A, et al. Drug-eluting stent for left main coronary artery disease. The DELTA registry: a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. JACC Cardiovasc Interv 2012;5:718-27.10.1016/j.jcin.2012.03.02222814776Search in Google Scholar

[55] Chang K, Koh YS, Jeong SH, et al. Long-term outcomes of percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main coronary bifurcation disease in the drug-eluting stent era. Heart 2012; 98:799-805.10.1136/heartjnl-2011-30075322422589Search in Google Scholar

[56] Lopes RD, Hafley GE, Allen KB, et al. Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. N Engl J Med 2009;361:235-44.10.1056/NEJMoa090070819605828Search in Google Scholar

[57] Barnard JB, Keenan DJ. National Institute for Health and Clinical Excellence. Endoscopic saphenous vein harvesting for coronary artery bypass grafts: NICE guidance.Heart 2011;97:327-9.10.1136/hrt.2010.20966821148577Search in Google Scholar

[58] Williams JB, Peterson ED, Brennan JM, et al. Association between endoscopic vs open vein-graft harvesting and mortality, wound complications, and cardiovascular events in patients undergoing CABG surgery. JAMA 2012;308:475-84.10.1001/jama.2012.8363369919722851114Search in Google Scholar

[59] Grant SW, Grayson AD, Zacharias J, et al. What is the impact of endoscopic vein harvesting on clinical outcomes following coronary artery bypass graft surgery? Heart 2012;98:60-4.10.1136/heartjnl-2011-30060021990387Search in Google Scholar

[60] Pepper JR. NICE guidance for off-pump CABG: keep the pump primed. Heart 2011;97:1728-30.10.1136/heartjnl-2011-30083621890866Search in Google Scholar

[61] Falk V, Taggart DP. NICE guidance for off-pump CABG: turn off the pump. Heart 2011;97:1731-3.10.1136/hrt.2011.22596121795296Search in Google Scholar

[62] Møller CH, Perko MJ, Lund JT, et al. Three-year follow-up in a subset of high-risk patients randomly assigned to off-pump versus on-pump coronary artery bypass surgery: the Best Bypass Surgery trial. Heart 2011;97:907-13.10.1136/hrt.2010.21168021415073Search in Google Scholar

[63] Hattler B, Messenger JC, Shroyer AL, et al. Veterans Affairs Randomized On/Off Bypass (ROOBY) Study Group.Off-Pump coronary artery bypass surgery is associated with worse arterial and saphenous vein graft patency and less effective revascularization: results from the Veterans Affairs Randomized On/Off Bypass (ROOBY) trial. Circulation 2012;125:2827-35.10.1161/CIRCULATIONAHA.111.069260Search in Google Scholar

[64] Anastasiadis K, Argiriadou H, Kosmidis MH, et al. Neurocognitive outcome after coronary artery bypass surgery using minimal versus conventional extracorporeal circulation: a randomised controlled pilot study. Heart 2011;97:1082-8.10.1136/hrt.2010.218610Search in Google Scholar

[65] Er F, Nia AM, Dopp H, et al. Ischemic preconditioning for prevention of contrast medium-induced nephropathy: randomized pilot RenPro Trial (Renal Protection Trial).Circulation 2012;126:296-303.10.1161/CIRCULATIONAHA.112.096370Search in Google Scholar

[66] Xie JJ, Liao XL, Chen WG, et al. Remote ischaemic preconditioning reduces myocardial injury in patients undergoing heart valve surgery: randomised controlled trial.Heart 2012;98:384-8.10.1136/heartjnl-2011-300860Search in Google Scholar

[67] Bøtker HE, Kharbanda R, Schmidt MR, et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 2010;375:727-34.10.1016/S0140-6736(09)62001-8Search in Google Scholar

[68] Rahman IA, Mascaro JG, Steeds RP, et al. Remote ischemic preconditioning in human coronary artery bypass surgery: from promise to disappointment? Circulation 2010;122(11 Suppl):S53-9.10.1161/CIRCULATIONAHA.109.92666720837926Search in Google Scholar

[69] D’Ascenzo F, Cavallero E, Moretti C, et al. Remote ischaemic preconditioning in coronary artery bypass surgery: a meta-analysis. Heart 2012;98:1267-71.10.1136/heartjnl-2011-30155122875822Search in Google Scholar

[70] Battipaglia I, Scalone G, Milo M, et al. Upper arm intermittent ischaemia reduces exercise-related increase of platelet reactivity in patients with obstructive coronary artery disease. Heart 2011;97:1298-303.10.1136/hrt.2011.22641521642242Search in Google Scholar

[71] Pedersen CM, Schmidt MR, Barnes G, et al. Bradykinin does not mediate remote ischaemic preconditioning or ischaemia-reperfusion injury in vivo in man. Heart 2011;97:1857-61.10.1136/heartjnl-2011-30032321873443Search in Google Scholar

[72] Moons KG, Kengne AP, Woodward M, et al. Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. Heart 2012;98:683-90.10.1136/heartjnl-2011-30124622397945Search in Google Scholar

[73] Moons KG, Kengne AP, Grobbee DE, et al. Risk prediction models: II. External validation, model updating, and impact assessment. Heart 2012;98:691-8. 10.1136/heartjnl-2011-30124722397946Search in Google Scholar

[74] Hemingway H, Philipson P, Chen R, et al. Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease. PLoS Med 2010;7: e1000286.10.1371/journal.pmed.1000286287940820532236Search in Google Scholar

[75] Sutaria S, Philipson P, Fitzpatrick NK, et al. Translational phases of evidence in a prognostic biomarker: a systematic review and meta-analysis of natriuretic peptides and the prognosis of stable coronary disease. Heart 2012;98:615-22.10.1136/heartjnl-2011-30086222388698Search in Google Scholar

[76] Beatty AL, Ku IA, Christenson RH, et al. High-sensitivity cardiac troponin T levels and secondary events in outpatients with coronary heart disease from the heart and soul study. JAMA Intern Med 2013;173:763-9.10.1001/jamainternmed.2013.116371988023568589Search in Google Scholar

[77] Omland T, Pfeffer MA, Solomon SD, et al. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease.J Am Coll Cardiol 2013;61:1240-9.10.1016/j.jacc.2012.12.02623414791Search in Google Scholar

[78] Korosoglou G, Lehrke S, Mueller D, et al. Determinants of troponin release in patients with stable coronary artery disease: insights from CT angiography characteristics of atherosclerotic plaque. Heart 2011;97:823-31.10.1136/hrt.2010.19320120884786Search in Google Scholar

[79] Brouwers FP, de Boer RA, van der Harst P, et al. Influence of age on the prognostic value of mid-regional pro-adrenomedullin in the general population. Heart 2012;98:1348-53.10.1136/heartjnl-2012-30239022821276Search in Google Scholar

[80] Held C, Hjemdahl P, Eriksson SV, et al. Prognostic implications of intima-media thickness and plaques in the carotid and femoral arteries in patients with stable angina pectoris. Eur Heart J 2001;22:62-72.10.1053/euhj.1999.200611133211Search in Google Scholar

[81] Xie W, Liang L, Zhao L, et al. Combination of carotid intima-media thickness and plaque for better predicting risk of ischaemic cardiovascular events. Heart 2011;97:1326-31.10.1136/hrt.2011.22303221653216Search in Google Scholar

[82] Den Ruijter HM, Peters SA, Anderson TJ, et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA 2012;308:796-803.10.1001/jama.2012.963022910757Search in Google Scholar

[83] Lorenz MW, Polak JF, Kavousi M, et al. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. Lancet 2012;379:2053-62.10.1016/S0140-6736(12)60441-3Search in Google Scholar

[84] Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010;341:c3691.10.1136/bmj.c3691291245920671013Search in Google Scholar

[85] Li K, Kaaks R, Linseisen J, et al. Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition study (EPIC-Heidelberg). Heart 2012;98:920-5.10.1136/heartjnl-2011-30134522626900Search in Google Scholar

[86] Williams DM, Fraser A, Lawlor DA. Associations of vitamin D, parathyroid hormone and calcium with cardiovascular risk factors in US adolescents. Heart 2011;97:315-20.10.1136/hrt.2010.203224393119421193684Search in Google Scholar

[87] Grandi NC, Brenner H, Hahmann H, et al. Calcium, phosphate and the risk of cardiovascular events and all-cause mortality in a population with stable coronary heart disease.Heart 2012;98:926-33.10.1136/heartjnl-2011-30080622301505Search in Google Scholar

[88] Grandi NC, Breitling LP, Hahmann H, et al. Serum parathyroid hormone and risk of adverse outcomes in patients with stable coronary heart disease. Heart 2011;97:1215-21. 10.1136/hrt.2011.22352921586795Search in Google Scholar